Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting

Overview

Release date: December 1, 2022
Expiration date: December 1, 2023
Estimated time to complete: 45 minutes

Provider Statement

Jointly provided by
 

Activity Description

In recent years, there have been significant advances in multiple myeloma (MM) management, including approvals of new drugs and treatment combinations. For some patients, however, the benefits of these advances remain elusive: disparities in MM care among Black patients, who are more likely to be treated in the community setting, persist across the spectrum of MM care.

Though evidence-based MM treatment guidelines and consensus statements are available, ongoing studies continue to provide information—on such issues as optimal regimen selection, the role of minimal residual disease (MRD) as a treatment goal, the use of emerging targeted and immunotherapeutic therapies, and management of treatment-related toxicities—that is potentially relevant to optimizing outcomes but that is likely not reflected in current guidelines. These advances pose formidable challenges to community oncology health care providers (HCPs).

This activity, developed for hematologist-oncologists, medical oncologists, and other HCPs, has been designed to bridge the gap between prevailing but potentially suboptimal MM treatment practices and novel recommended therapies and to ensure that clinicians are able to apply evidence that can lead to improved patient outcomes in diverse MM patient populations.

Faculty

Craig Emmitt Cole, MD
Assistant Professor of Medicine
Michigan State University College of Human Medicine
Karmanos Cancer Institute
Lansing, Michigan

Laura Finn, MD, MS
Director Hematology/Bone Marrow Transplant
Ochsner Health
New Orleans, Louisiana

Joshua Richter, MD
Associate Professor of Medicine
Tisch Cancer Institute/Icahn School of Medicine at Mount Sinai
Director of Myeloma: Blavatnik Family – Chelsea Medical Center at Mount Sinai
New York, New York

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other HCPs involved in the care of patients with MM.

Learning Objectives

Upon completion of this activity, participants should be better able to (1) interpret cytogenetic, molecular, and other standard staging tests used to define risk and prognosis for patients with MM; (2) distinguish between the indicated uses and mechanisms of action of current and emerging treatment regimens in the frontline and relapsed settings; (3) evaluate emerging data regarding the approach to MRD testing; and (4) develop individualized management plans for MM patients based on disease-, regimen-, and patient-related factors.

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, the Multiple Myeloma Research Foundation, and RedMedEd. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

In accordance with the ACCME Standards for Integrity and Independence, all CE providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 24 months with an ineligible company whose products or services are discussed in the CE activity content over which the individual has control.

All of the relevant financial relationships listed for these individuals have been mitigated. Relationship information appears below:

Craig Emmitt Cole, MD, has disclosed the following relevant financial relationships:
Consultant: AbbVie, AstraZeneca, Oncopeptides, Sanofi

Laura Finn, MD, MS, has disclosed the following relevant financial relationships:
Consultant: Janssen
Speakers Bureau: BeiGene, Bristol Myers Squibb, Jazz Pharmaceuticals, Janssen, Lilly

Joshua Richter, MD, has disclosed the following relevant financial relationships:
Consultant, Advisor: Adaptive Biotechnologies, Celgene/Bristol Myers Squibb, Janssen, Karyopharm, Oncopeptides, Sanofi, Secura Bio, Takeda, X4 Pharmaceuticals
Speakers Bureau: Adaptive Biotechnologies, Bristol Myers Squibb, Janssen, Sanofi

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation
The Multiple Myeloma Research Foundation planners have disclosed no relevant financial relationships.

RedMedEd
The RedMedEd planners have disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine, the Multiple Myeloma Research Foundation, RedMedEd, AbbVie, BMS, and Janssen. do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine, the Multiple Myeloma Research Foundation, RedMedEd, AbbVie, BMS, or Janssen. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest and program evaluation. Certificates can be printed immediately.

Contact Information

For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code PSCM Activity Code G6832-22-T.

Hardware/Software Requirements

A computer, iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection using one of these browsers: Chrome, Firefox, Safari, Microsoft Edge.

Privacy

CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through Penn State College of Medicine or RedMedEd. For more information, contact ContinuingEd@hmc.psu.edu or education@redmeded.com.

Copyright

© 2022. This CME-certified program is held as copyrighted by Penn State College of Medicine, the Multiple Myeloma Research Foundation, and RedMedEd. Through this notice, Penn State College of Medicine, the Multiple Myeloma Research Foundation, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.